PMVP

SEC source: 0001209191-21-039028 · doc4.xml · derivative · entry 1

Mack David Henry · CIK 0001341642 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,584

Underlying: Common Stock · 134,584 shares

Expires 2031-05-11

F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2021.

SEC source: 0001209191-21-039038 · doc4.xml · derivative · entry 1

Jalota Deepika · CIK 0001825192 · SVP, Regulatory Affairs and QA

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,674

Underlying: Common Stock · 22,674 shares

Expires 2031-05-11

F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2021.

SEC source: 0001209191-21-039035 · doc4.xml · derivative · entry 4

Alland Leila · CIK 0001825216 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,279

Underlying: Common Stock · 36,279 shares

Expires 2031-05-11

F4 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on June 12, 2021.

SEC source: 0001209191-21-047747 · doc4.xml · derivative · entry 2

LEVINE ARNOLD J · CIK 0001124164 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,781

Underlying: Common Stock · 5,781 shares

Expires 2031-05-11

F3 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on June 12, 2021.

SEC source: 0001209191-21-047970 · doc4.xml · derivative · entry 1

Heyman Richard A. · CIK 0001584759 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,781

Underlying: Common Stock · 5,781 shares

Expires 2031-05-11

F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on June 12, 2021.

SEC source: 0000899243-21-019183 · doc4.xml · nonDerivative · entry 6

INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner

InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner

NASR KHALED · CIK 0001276600 · 10% owner

Desai Keval · CIK 0001553019 · 10% owner

Kliman Gilbert H · CIK 0001293171 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Gilbert H. Kliman

Disclosed balance after: 3,404

F2 · kind: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 186 shares distributed to Khaled A. Nasr ("Nasr"), 125 shares distributed to Keval Desai ("Desai") and 1,135 shares distributed to Gilbert H. Kliman ("Kliman").

F3 · ownership.nature: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein.

SEC source: 0000899243-21-019183 · doc4.xml · nonDerivative · entry 5

INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner

InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner

NASR KHALED · CIK 0001276600 · 10% owner

Desai Keval · CIK 0001553019 · 10% owner

Kliman Gilbert H · CIK 0001293171 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By: Keval Desai

Disclosed balance after: 375

F2 · kind: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 186 shares distributed to Khaled A. Nasr ("Nasr"), 125 shares distributed to Keval Desai ("Desai") and 1,135 shares distributed to Gilbert H. Kliman ("Kliman").

F3 · ownership.nature: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein.

SEC source: 0000899243-21-019183 · doc4.xml · nonDerivative · entry 4

INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner

InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner

NASR KHALED · CIK 0001276600 · 10% owner

Desai Keval · CIK 0001553019 · 10% owner

Kliman Gilbert H · CIK 0001293171 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By: Khaled A. Nasr

Disclosed balance after: 559

F2 · kind: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 186 shares distributed to Khaled A. Nasr ("Nasr"), 125 shares distributed to Keval Desai ("Desai") and 1,135 shares distributed to Gilbert H. Kliman ("Kliman").

F3 · ownership.nature: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein.

SEC source: 0000899243-21-019183 · doc4.xml · nonDerivative · entry 3

INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner

InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner

NASR KHALED · CIK 0001276600 · 10% owner

Desai Keval · CIK 0001553019 · 10% owner

Kliman Gilbert H · CIK 0001293171 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By: InterWest Management Partners X, LLC

Disclosed balance after: 0

F2 · kind: Represents pro rata in-kind distribution by IMP10 without consideration to its members in accordance with the terms of the InterWest Management Partners X, LLC Operating Agreement. Includes 186 shares distributed to Khaled A. Nasr ("Nasr"), 125 shares distributed to Keval Desai ("Desai") and 1,135 shares distributed to Gilbert H. Kliman ("Kliman").

F3 · ownership.nature: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein.

SEC source: 0000899243-21-019183 · doc4.xml · nonDerivative · entry 2

INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner

InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner

NASR KHALED · CIK 0001276600 · 10% owner

Desai Keval · CIK 0001553019 · 10% owner

Kliman Gilbert H · CIK 0001293171 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By: InterWest Management Partners X, LLC

Disclosed balance after: 5,000

F1 · kind: Represents pro rata in-kind distribution by InterWest Partners X, LP ("IW10") without consideration to its limited and general partners in accordance with the terms of the InterWest Partners X, LP Limited Partnership Agreement. Includes 5,000 shares distributed to InterWest Management Partners X, LLC ("IMP10") its general partner.

F3 · ownership.nature: The shares are held directly by IW10. The general partner of IW10 is IMP10. Kliman is a Managing Director of IMP10 and Nasr and Desai are Venture Members of IMP10. Each of Nasr, Desai and Kliman share voting and investment control over the shares owned by IW10, and may be deemed to beneficially own the shares held by IW10. Each of Nasr, Desai and Kliman disclaims beneficial ownership of such shares except to the extent of his pecuniaryinterest theriein.

SEC source: 0000899243-21-019183 · doc4.xml · nonDerivative · entry 1

INTERWEST PARTNERS X LP · CIK 0001443898 · 10% owner

InterWest Management Partners X, LLC · CIK 0001460207 · 10% owner

NASR KHALED · CIK 0001276600 · 10% owner

Desai Keval · CIK 0001553019 · 10% owner

Kliman Gilbert H · CIK 0001293171 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,969,911

F1 · kind: Represents pro rata in-kind distribution by InterWest Partners X, LP ("IW10") without consideration to its limited and general partners in accordance with the terms of the InterWest Partners X, LP Limited Partnership Agreement. Includes 5,000 shares distributed to InterWest Management Partners X, LLC ("IMP10") its general partner.

SEC source: 0001209191-21-032222 · doc4.xml · nonDerivative · entry 1

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,104,414

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.60 to 35.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-031300 · doc4.xml · derivative · entry 4

Alland Leila · CIK 0001825216 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 369,850

Underlying: Common Stock · 4,000 shares

Expires 2030-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter.

SEC source: 0001209191-21-031300 · doc4.xml · nonDerivative · entry 3

Alland Leila · CIK 0001825216 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.47 to $35.50, inclusive.

SEC source: 0001209191-21-031300 · doc4.xml · nonDerivative · entry 2

Alland Leila · CIK 0001825216 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.30 to $35.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

SEC source: 0001209191-21-031300 · doc4.xml · nonDerivative · entry 1

Alland Leila · CIK 0001825216 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-031052 · doc4.xml · nonDerivative · entry 1

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,106,201

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.60 to 35.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-030096 · doc4.xml · derivative · entry 3

Kung Winston · CIK 0001666963 · COO, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,534

Underlying: Common Stock · 4,500 shares

Expires 2028-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option is subject to an early exercise provision and is immediately exercisable. The underlying shares vest in accordance with the terms of the option grant.

SEC source: 0001209191-21-030096 · doc4.xml · nonDerivative · entry 2

Kung Winston · CIK 0001666963 · COO, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,600

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2020.

SEC source: 0001209191-21-030096 · doc4.xml · nonDerivative · entry 1

Kung Winston · CIK 0001666963 · COO, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,100

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-026547 · doc4.xml · nonDerivative · entry 5

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,106,801

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-026547 · doc4.xml · nonDerivative · entry 4

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,106,901

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.92 to $32.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-026547 · doc4.xml · nonDerivative · entry 3

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,107,801

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.86 to $31.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-026547 · doc4.xml · nonDerivative · entry 2

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,110,704

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.34 to $35.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-026547 · doc4.xml · nonDerivative · entry 1

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,130,562

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.27 to 34.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-026157 · doc4.xml · nonDerivative · entry 6

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,136,467

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.02 to $34.51 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-026157 · doc4.xml · nonDerivative · entry 5

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,157,168

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.02 to $34.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-026157 · doc4.xml · nonDerivative · entry 4

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,169,789

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-026157 · doc4.xml · nonDerivative · entry 3

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,169,889

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.26 to $34.23 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-026064 · doc4.xml · derivative · entry 4

Alland Leila · CIK 0001825216 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 373,850

Underlying: Common Stock · 4,000 shares

Expires 2030-02-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter.

SEC source: 0001209191-21-026064 · doc4.xml · nonDerivative · entry 3

Alland Leila · CIK 0001825216 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.37 to $34.50, inclusive.

SEC source: 0001209191-21-026064 · doc4.xml · nonDerivative · entry 2

Alland Leila · CIK 0001825216 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.33 to $34.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

SEC source: 0001209191-21-026064 · doc4.xml · nonDerivative · entry 1

Alland Leila · CIK 0001825216 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-21-026157 · doc4.xml · nonDerivative · entry 2

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,194,246

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.13 to $35.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-026157 · doc4.xml · nonDerivative · entry 1

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,261,332

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.11 to 34.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-025463 · doc4.xml · nonDerivative · entry 3

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,272,903

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.83 to $34.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-025463 · doc4.xml · nonDerivative · entry 2

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,302,106

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.83 to $33.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-025880 · doc4.xml · derivative · entry 1

BAUM CHARLES M · CIK 0001579824 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,677

Underlying: Common Stock · 32,677 shares

Expires 2031-04-05

F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on May 5, 2021.

SEC source: 0001209191-21-025463 · doc4.xml · nonDerivative · entry 1

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,321,096

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.42 to $33.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-023909 · doc4.xml · nonDerivative · entry 7

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,333,531

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.79 to $33.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-023909 · doc4.xml · nonDerivative · entry 6

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,347,176

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.79 to $32.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-023909 · doc4.xml · nonDerivative · entry 5

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,365,557

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.74 to $31.58 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-023909 · doc4.xml · nonDerivative · entry 4

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,367,157

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.07 to $31.40 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-023909 · doc4.xml · nonDerivative · entry 3

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,370,433

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.07 to $31.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-023909 · doc4.xml · nonDerivative · entry 2

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,389,640

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.04 to $33.62 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-023909 · doc4.xml · nonDerivative · entry 1

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,390,404

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.32 to $32.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-023299 · doc4.xml · nonDerivative · entry 8

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,391,814

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.85 to $33.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-023299 · doc4.xml · nonDerivative · entry 7

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,427,082

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.64 to $35.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-023299 · doc4.xml · nonDerivative · entry 6

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,428,282

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.58 to $34.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.

SEC source: 0001209191-21-023299 · doc4.xml · nonDerivative · entry 5

Schroeder Thilo · CIK 0001776412 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,432,069

F1 · kind: Shares were sold pursuant to a Rule 10b5-1 trading plan.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $33.46 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.